Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

Recently, Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous market value. If it gets a green light, as expected, the ...

23andMe, known for its at-home DNA testing kits, is expected to be obtained by its highest bidder following a bankruptcy auction after reaching a peak valuation of $6 billion.

Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S.

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals ... outlining his ...

States with privacy objections to the sale have until July 7 to reach a stay to appeal the case. TTAM, a nonprofit started by ...

Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, retailers and other industry ...